OPNT News and Press, Opiant Pharmaceuticals Inc. From 04/05/21

Opiant Pharmaceuticals (OPNT) announces that the first subjects were dosed in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist OPNT003, nasal nalmefene, with nasal naloxone.The single-center, randomized, open-label study in heathy volunte...

Pharmacodynamic study will compare OPNT003, nasal nalmefene, with nasal naloxone in reversing the respiratory depression produced by the synthetic opioid, remifentanil Top-line data expected in the fourth quarter This trial starts at a time when deaths resulting ...

Opiant Pharmaceuticals (OPNT) has been awarded the third and final tranche of $1.8M from the total grant of about $7.4M from the National Institute on Drug Abuse, part of the National Institutes of Health, to support the development of OPNT003, nasal nalmefene, for the treatment of opioi...

SANTA MONICA, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, has been awarded the third and final tranche of $1.8 millio...

SANTA MONICA, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the appointment of Lorianne Masuoka, M.D., to it...

Opiant Pharmaceuticals, Inc. (OPNT) Q4 2020 Earnings Conference Call March 4, 2021 4:30 PM ET Company Participants Ben Atkins – Vice President-Investor Relations Roger Crystal – Chief Executive Officer David O'Toole – Chief Financial Officer Conference Call Participants B...

Opiant Pharmaceuticals (OPNT): Q4 GAAP EPS of -$0.16 misses by $0.23.Revenue of $10M (+30.4% Y/Y) beats by $0.8M.Shares -3.2%.Press Release For further details see: Opiant Pharmaceuticals EPS misses by $0.23, beats on revenue

SANTA MONICA, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the fourth quarter and year...

SANTA MONICA, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its financial results for the four...

Opiant Pharma (OPNT) announced the dosing of the first patient in a confirmatory pharmacokinetic ((PK)) study for OPNT003, nasal nalmefene, for the treatment of opioid overdose, with study results expected by June 2021.The open label, randomized, crossover study will enroll 68 healthy vo...